Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.

Applying the previously established MRD threshold of VAF >0.01% by NGS/DNA in the enlarged cohort, resulted in 37 patients (12%) with relatively high-level mutant NPM1 disease and a highly significant increased risk of relapse (4-year CIR: 52.8% MRD + vs 28.1% MRD – ; HR, 2.56; 95% CI, 1.54-4.25; P < .001; Figure 3 D), and inferior OS ( P > .001; supplemental Figure 5 D).

also in 132,142 other papers